Sulphasalazine in the treatment of children with chronic arthritis

Clinical Rheumatology

Volumn 17, Issue 5, 1998, Pages 359-363

  Huang, Jing Long ^a,b   Chen, Li Chen ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG CHILDREN S HOSPITAL   (Taiwan)

Author keywords

Juvenile rheumatoid arthritis; Juvenile spondyloarthropathies; Sulphasalazine

Indexed keywords

HEMOGLOBIN; HLA B27 ANTIGEN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADOLESCENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC ARTHRITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SPONDYLOARTHROPATHY; VERTIGO; VOMITING;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; DIARRHEA; DIZZINESS; FEMALE; FOLLOW-UP STUDIES; HEADACHE; HUMANS; JOINT DISEASES; MALE; RETROSPECTIVE STUDIES; SPINAL DISEASES; SPONDYLITIS, ANKYLOSING; SULFASALAZINE; TREATMENT OUTCOME; VOMITING;

EID: 0031760601     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01450892     Document Type: Article

References (32)

1. McConkey B, Amos RS, Butcher RA, et al. Sulphasalazine in rheumatoid arthritis. Br Med J 1980;279:442-4.
2. Neumann VC, Grundulis KA, Hubball S, et al. Comparison between penicillamine and sulphasalazine in rheumatoid arthritis. Br Med J 1983;287:1099-102.
3. Bax DE, Amos RS. Sulphasalazine: a safe effective agent for prolonged control of rheumatoid arthritis: a comparison with sodium aurothiomalate. Ann Rheum Dis 1985;44:194-8.
4. Nissila M, Lehtinen K, Leirisalo-Repo M, Luukhainen R, Mutru O, Yli-Kertula U. Sulphasalazine in the treatment of ankylosing spondylitis. Arthritis Rheum 1988;31:1111-6.
5. Kirwan J, Edwards A, Huitfeldt B, Thompson P, Currey H. The course of establishing ankylosing spondylitis and the effects of sulphasalazine over 3 years. Br J Rheumatol 1993;32:729-33.
6. Dougados M, Boumier P, Amor B. Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients. Br Med J 1986;293:911-4.
7. Pullar T, Hunter JA, Capell HA. Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br Med J 1983;287:1102-4.
8. Pinala RS, Kaplan SB, Lawson JG, Hepburn B. Sulfasalazine in rheumatoid arthritis: a double-blind, placebo-controlled trial. Arthritis Rheum 1986;29:1427-34.
9. Williams HJ, Ward JR, Dahl SL, et al. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis Rheum 1988;31:702-13.
10. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalysis. Arthritis Rheum 1990;33:1449-61.
11. Nuver-Zwart IH, van Riel PLCM, van de Putte LBA, Gribnau FWJ. A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine. Ann Rheum Dis 1989;48:389-95.
12. Wijnands MJH, van Hof MA, van Leeuwen MA, van Rijswijle MH, van de Putte LBA, van riel PLCM. Long-term second-line treatment: a prospective drug survival study. Br J Rheumatol 1992;31:253-8.
13. Hannonen P, Mottonen T, Hakola M, Oka M. Sulfasalazine in early rheumatoid arthritis: a 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 1993;36:1501-9.
14. Ozdogan H, Turuns M, Deringol B, Yurdakul S, Yazici H. Sulphasalazine in the treatment of rheumatoid arthritis: a preliminary open trial. J Rheumatol 1986;13:124-5.
15. Imundo LF, Jacobs JC. Treatment of juvenile arthritis (JA) with sulphasalazine. Arthritis Rheum 1993;36(suppl):s122.
16. Joos R, Veys EM, Mielants H, van Werveke S, Goemaere S. Sulfasalazine treatment in juvenile chronic arthritis: an open study. J Rheumatol 1991;18:880-4.
17. Ansell BM, Hall MA, Loftus JK, et al. A multicenter pilot study of sulphasalazine in juvenile chronic arthritis. Clin Exp Rheumatol 1991;9:201-3.
18. Job-Deslandre C, Menkes CJ. Sulphasalazine in the treatment of juvenile spondyloarthropathy. Arthritis Rheum 1991;34 (suppl):s153.
19. Susche HJ. Treatment of juvenile spondyloarthritis and reactive arthritis with sulphasalazine. Monatsschr Kinderheilkd 1992;140:658-60.
20. Burgos-Vargas R, Pacheco-Tena C, Vazguez-Mellado J. Juvenile-onset spondyloarthropathy. Rheum Dis Clin North Am 1997;23:569-99.
21. Brewer EJ, Bass J, Baum J, et al. Current proposed revision of JRA criteria. Arthritis Rheum 1977;20(suppl):195-9.
22. Bennett BH, Birch TA. New York symposium on population studies in the rheumatic diseases: new diagnostic criteria. Bull Rheum Dis 1967;25:1041-7.
23. Rosenberg AM, Petty RE. A syndrome of seronegative enthesopathy and arthropathy in children. Arthritis Rheum 1982;25:1041-7.
24. Cabral DA, Oen Kg, Petty RE. SEA syndrome revisited: a longterm follow-up of children with a syndrome of seronegative enthesopathy and arthropathy. J Rheumatol 1992;19:1282-5.
25. Burgos-Vargas R, Clark P. Axial involvement of the seronegative enthesopathy and arthropathy syndrome and its progression to ankylosing spondylitis. J Rheumatol 1989;16:192-7.
26. Hussein A, Abdul-Khaliq H, von der Hardt H. Atypical spondyloarthritis in children: proposed diagnostic criteria. Eur J Pediatr 1989;148:513-7.
27. Jacobs JC, Berdon WE, Johnston AD. HLA-B27-associated spondyloarthritis and enthesopathy in childhood: clinical, pathologic, and radiographic observations in 58 patients. J Pediatr 1982;100:521-8.
28. Hawkey CJ, Truelove SC. Inhibition of prostaglandin synthetase in human rectal mucosa. Gut 1983;24:213-7.
29. Rhodes JM, Bartholomew TC, Jewell DP. Inhibition of leukocyte motility by drugs used in ulcerative colitis. Gut 1981;22:642-7.
30. Carter SD, Bacon PA, Hall ND. Characterization of activated lymphocytes in the peripheral blood of patients with rheumatoid arthritis. Ann Rheum Dis 1981;40:293-8.
31. Madhok R, Wijelath E, Smith J, Watson J, Sturrock RD, Capell HA. Is the beneficial effect of sulphasalazine due to inhibition of synovial neovascularization? J Rheumatol 1991;18:199-202.
32. Greenfield SM, Hamblin AS, Shakoor ZS, Teare JP, Punchard NA, Thompson RPH. Inhibition of leukocyte adhesion molecule upregulation by tumor necrosis factor: a novel mechanism of action of sulphasalazine. Gut 1993;34:256-6.